Treatment of the ARHGAP5‐AS1‐KD HCC cells with the 26S protostome inhibitor MG132 increased the expression of endogenous CSDE1 protein in comparison with the control HCC cells (Figure 4G). Here, ARHGAP5 is linked to hepatocellular carcinoma.